Roaring out of the gate this morning with a 21.70% gain ($0.74) is SciClone Pharmaceuticals (SCLN) http://www.sciclone.com/ now trading in the $4.14 range on the Nasdaq with a new market cap of $187 million. SCLN nearly quadrupled its 3-Month average daily trading volume of 318,403 shares topping 1,125,760 shares traded by 11 a.m. EST.
Late yesterday, SCLN reported a Q2 09 net income of $7.3 million, or 16 cents a share, compared to a loss in the same period last year of $300,000, or 1 cent a share. SCLN revenue grew 59% to $22 million compared with the same period in 2008. SCLN
SCLN management also updated its financial guidance for 2009: anticipating full year 2009 revenue of between $69 and $71 million, an increase of approximately 28 percent to 31 percent over 2008. SCLN anticipates earnings per share for the full year 2009 to be between 10 cents and 14 cents a share.
SCLN makes drugs for the treatment of cancer and infectious diseases in China and internationally. It provides ZADAXIN for the treatment of hepatitis B and hepatitis C, and certain cancers, as well as for use as a vaccine adjuvant.
SCLN has an impressive pipeline that includes: ZADAXIN, a thymalfasin, which is in Phase III clinical trials for the treatment of stage IV melanoma; RP101, which is in Phase II clinical trials for the treatment of pancreatic cancer; and SCV-07, which is in Phase II clinical trials for the treatment of hepatitis C virus and oral mucositis. SCLN also holds Chinese marketing rights from Biocompatibles International for DC Bead, a product for the treatment of liver cancer.
While certain Q2 comparables are still unavailable as of this writing, SCLN Q1 figures for the period ending 03-31-09 could in effect provide a 'tale-of-the-tape' for investors; for example, in Q1, SCLN had product sales of $15,069,000 and measured against full year 2007 of $ 37,038,000 and full year 2006 of $32,433,000, if Q2 sales held near Q1 levels, SCLN could be on its way to a record year. Q1 clinical trials expense came in at $297,000 and SCLN had cash, term deposits and a money market fund all totaling $22,078,000. If Q2 numbers hold true to Q1 and SCLN retained a Q2 $6 million line of credit with Silicon Valley Bank it held in Q1, the company would have ample reserves to deliver its drugs through trials and to market commercialization.
At $4.14, SCLN will set a 52-week high today. Its 52-week low was $0.63 set on 12-31-08. At $4.14, SCLN is above both its 50-day and 200-day moving averages. SCLN has trailing twelve month revenues of $46 million. Its shares out versus float ratio is close enough to parity to make it stable.
Also posting a significant jump on earnings news this morning is Cardtronics Inc., (CATM) http://www.cardtronics.com/ posting a 32.86% gain ($1.95). CATM is currently trading in the $6.44 range with a new market cap of $260 million. CATM has a 3-Month average daily trading volume of 60,916 shares and had surpassed 484,791 shares traded by 11 a.m. EST.
CATM Q2 09 earnings were 17 cents a share, beating estimates of a nickel. The 12 cent difference sent CATM stock flying. CATM revenues fell a modest 1.9%. CATM management also boosted total 2009 guidance of EPS to $0.40-0.50, up from $0.12-0.22.
CATM owns and operates 32,950 automated teller machines (ATMs) in the United States, the United Kingdom, and Mexico. At $6.44, CATM is below its 52-week high of $9.32 set on 08-07-08 and is far above its 52-week low of $0.47 set on 11-21-08 (a good buy signal). At $6.44 CATM is well ahead of both its 50-day and 200-dau moving averages. CATM has trailing twelve month revenues of $487. CATM is largely held by institutions and insiders. I would certainly like to see more shares in the public float.
Picking up a modest 4.87% ($1.25) this morning on earnings news is Atlas Air Worldwide Holdings (AAWW) http://www.atlasair.com/. But any gain in the airline industry is worth noting. AAWW is currently trading in the $26.14 range on the Nasdaq with a new market cap of $547 million. AAWW has a 3-Month average daily trading volume of 343,923 shares and easily surpassed that hours into the session.
AAWW Q2 09 EPS beat the 40 cent estimates of analysts by 13 cents coming in at 53 cents. AAWW reported a higher-than-expected quarterly profit due to cost cutting measures amidst recession's forced drop in freight traffic. For the first six months; AAWW earnings came to $34.7 million or $1.66 a diluted share, compared with a loss of $3.8 million, or 18 cents a share, a year earlier. Good news, AAWW is finally off the tarmac.
AAWW provides aircraft and outsourced aircraft operating solutions to the air freight industry. It operates in four segments: Aircraft, Crew, Maintenance, and Insurance.
At $26.14, AAWW is less-than-half its 52-week high of $59.03 set on 09-02-08 and is triple-plus its 52-week low of $8.99 (another good buy signal). At $26.a4, AAWW is ahead of both its 50-day and 200-day moving averages, AAWW had trailing twelve month revenues of $1.48 billion and a trailing twelve month diluted EPS of $4.34. It shares out versus float ratio is near-parity.
Finally today, Bio-Tech company Novavax Inc., (NVAX) http://www.novavax.com/ gained 13.39% ($0.62) on news that it had created a version of the swine flu virus for use in a potential vaccine. That announcement more than doubled its 3-Month average daily trading volume of 5,370,530 shares; sending today's shares traded volume past 11,975,094. NVAX is currently trading in the $5.21 range. NVAX has a new market cap of $450 million.
NAVX management said it is using a gene sequence provided by the U.S. Centers for Disease Control to produce a virus-like particle, which is similar to particles of swine flu, but does not have the genes necessary to replicate. NAVX said it plans to make more of the particles into a vaccine for use in clinical studies and to meet demand. NAVX said it can deliver the vaccine in eleven weeks. That's quick.
NVAX is a clinical-stage biopharmaceutical company that focuses on developing vaccines using its virus-like particle platform technology for infectious diseases. It develops vaccines against the H5N1 and other subtypes of avian influenza with pandemic potential, human seasonal influenza, and Respiratory Syncytial Virus, as well as Varicella Zoster that causes shingles.
At $5.21, NVAX is two pennies away from its 52-week high of $5.23 set on 07-29-09 and is far above its 52-week low of $0.52 set on 04-02-09. I don't know if there's any money to be made in the short-term here, but a $6 threshold might be surpassed when the vaccine is delivered in 11 weeks. At $5.21, NAVX is ahead of both its 50-day and 200-day moving averages. Its shares out versus float ratio is near-parity.